1. Scrip
  2. >>Business
  3. >>Financing

With Blackstone’s $300m, Uniquity Will Take On Tezspire In Respiratory Disease

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Built around a TSLP-targeted antibody licensed from Merck, Uniquity begins with $300m from Blackstone to fund Phase II in asthma and COPD. But other anti-TSLP competition looms.

Lungs
Uniquity plans to compete with Tezspire in respiratory disease • Source: Shutterstock

Competition to Amgen, Inc. and AstraZeneca PLC’s anti-TSLP drug Tezspire (tezepelumab) is growing as Uniquity Bio moved out of stealth on 15 May with $300m from sole investor Blackstone and its own TSLP-targeting antibody solrikitug ready to enter Phase II in both asthma and chronic obstructive pulmonary disease (COPD).

Key Takeaways

  • Uniquity Bio gets $300m from Blackstone to fund Phase II studies of solrikitug, licensed from Merck, in asthma and chronic obstructive pulmonary disease.

In an interview, Uniquity CEO Brian Lortie said his company also has ambitions to test solrikitug, licensed from Merck...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.